MedTrace Logo

Gait Parameters After Using the Tilt-table Exercise and Motor Imagery.

NCT06748378 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2026-02-05

No results posted yet for this study

Summary

Sixty-six stroke patients were randomly assigned to three groups (conventional, with the addition of the Erigo®Pro table, and enriched with motor imagery). The Trunk Stability Test, walking speed, step symmetry, and lower limb load symmetry on the Riablo device, as well as the superficial tension of the transverse abdominis and multifidus muscles, were assessed before and after completing therapy.

Conditions

  • Stroke
  • Visualization
  • Gait Analysis

Interventions

PROCEDURE

Conventional rehabilitation, the Erigo®Pro table, motor imagery on gait.

66 stroke patients were randomly assigned to three groups (22 people each) with different therapies (conventional, with the addition of Erigo®Pro and enriched with motor imagery). The therapy duration was two weeks. Patients underwent assessment before and after completion of therapy. The study used the Trunk Stability Test, and the Riablo device to measure gate parameters. Additionally, an evaluation of the superficial tension of the transverse abdominis and multifidus muscles was conducted.

PROCEDURE

Conventional rehabilitation, the Erigo®Pro table, motor imagery on gait parameters.

66 stroke patients were randomly assigned to three groups (22 people each) with different therapies (conventional, with the addition of Erigo®Pro and enriched with motor imagery). The therapy duration was two weeks. Patients underwent assessment before and after completion of therapy. The study used the Trunk Stability Test, and the Riablo device to measure the gate parameters. Additionally, an evaluation of the superficial tension of the transverse abdominis and multifidus muscles was conducted.

Sponsors & Collaborators

  • Anna Olczak

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-01
Primary Completion
2025-07-15
Completion
2025-08-15

Countries

  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06748378 on ClinicalTrials.gov